The Drug Shortage Staff (DSS) was established in 1999 as part of the Center for Drug Evaluation & Research. Our mission is to prevent, mitigate and help resolve shortages as well as perform outreach to professional organizations, patient groups, the public and other stakeholders. Additionally, DSS facilitates prevention and resolution of shortages by working with key stakeholders from the FDA, other government agencies, industry, and the public.
FDA takes great efforts, within its legal authority, to address and prevent drug shortages, which can occur for many reasons, including manufacturing and quality problems, delays, and discontinuations. The agency works closely with manufacturers of drugs in short supply to communicate the issue and to help restore availability.
The majority of drug shortage information is provided to FDA by manufacturers. Communication between FDA and the public is an essential component of preventing and mitigating drug shortages. To ensure information is current, FDA appreciates all information and updates about shortages provided by manufacturers. Shortage notifications and updates may be reported to FDA at email@example.com.
FDA created this searchable database to provide stakeholders with easy access to information about drugs in shortage, such as product availability, supply, and estimated duration of shortage. The database includes information about current drugs in shortage, resolved shortages, discontinuations of specific drug products, corresponding therapeutic categories, resource information, and relevant links. The majority of information is provided to FDA by manufacturers. To ensure the information in this section is current, FDA relies on updates provided by manufacturers on a regular basis. We post updates on drug shortages as soon as we receive them from the manufacturers.